EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.
Also called NCT04743453
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 211 participants
- Registry
-
NCT04743453
-
- Other papers using this trial's data
- The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil
- Registry status
- Completed
Technical summary
Registry record NCT04743453. Randomized; double masking; primary purpose treatment. Start 2021-08-17 (actual); primary completion 2024-09-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.
- Condition
- Kidney Transplantation
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Diabetes Complications
- Intervention (Drug)
- Dapagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Sao Paulo General Hospital
- Collaborator
- Federal University of São Paulo
Record details
- Record id
cardio:ct-nct04743453- Content hash
acc841909639916f14a2164f94f39dcf9f6dbcbe6116a2e44a622126d0d60529